Human clostridium tetani toxoid immune globulin Drugbank ID : DB11604

Description : Indication : Pharmacodynamics : NA It is indicated for prophylaxis against tetanus following injury in patients whose immunization is incomplete or uncertain (see below). It is also indicated, although evidence of effectiveness is limited, in the regimen of treatment of active cases of tetanus. Pharmacodynamics : It supplies passive immunity to those individuals who have low or no immunity to the toxin produced by the tetanus organism, Clostridium tetani. The antibodies act to neutralize the free form of the powerful exotoxin produced by this bacterium. Mechanism of action :

Targets : Affected organisms : Categories : NA Humans and other mammals Categories :

Brands : Hypertet S/d Company : Grifols USA, LLC Description : HyperTET® S/D treated with solvent/detergent is a colorless to pale yellow or pink sterile solution of tetanus hyperimmune immune globulin for intramuscular administration; it is preservative-free, in a latex-free delivery system. HyperTET S/D is prepared by cold ethanol fractionation fromthe plasma of donors immunized with tetanus toxoid. Used for/Prescribed for : HyperTET S/D is indicated for prophylaxis against tetanus following injury in patients whose immunization is incomplete or uncertain (see below). It is also indicated, although evidence of effectiveness is limited, in the regimen of treatment of active cases of tetanus. Formulation : 250 [iU]/mL Form : Injection Route of administration : intramuscular

NA Albiglutide delays gastric emptying, and has the potential to impact the absorption of concomitantly administered oral medicinal products. It shows major interactions with acarbose, simvastatin, digoxin, warfarin and oral contraceptives.

References : https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=393fa198-7e07-4162-bd0a-9d873f1544a9&type=display http://www.drugbank.ca/drugs/DB11604